19th Bioshares Biotech Summit

Emerging Private Companies & IPOs

Damian Clarke-Bruce - CEO

Pioneering the development of immunotherapies for patients with blood cancers and b-cell disorders



HaemaLogiX

August, 2025

HaemaLogiX is:

Advancing highly selective and efficacious next-generation immunotherapies targeting malignant plasma cells

Preserving normal healthy plasma cells

Focusing on the US$23.3B multiple myeloma market – a disease without a cure

HaemaLogiX

HaemaLogiX's technology originated from research conducted at the University of Technology Sydney.

These innovations were led by our Scientific Founder and Director, Dr Rosanne Dunn.


Our thanks to Myeloma Australia
Who actively and expertly support Australians living with myeloma while driving progress towards cure.
Click to play
Myeloma Australia
HaemaLogiX

Multiple myeloma is the 2nd most common blood cancer

Multiple myeloma is a blood cancer with no cure that forms in white blood cells, known as “plasma cells”, within the bone marrow

Key statistics

~188,000
new cases per year worldwide[1]

~543,000
living with the disease worldwide[1]

42%
of patients die within five years[1]

>60%
of patients fail standard of care treatments and progress



Clinical unmet need

Infections cause **~51%** of non-progression-related deaths in multiple myeloma patients

Primary growth drivers

Increased prevalence
Ageing population[3]

Source: Cordas dos Santos et al. (2024) Nature Medicine

Sources: 1) Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2024; 74(3): 229-263. 2) IMWG 2020; CDC United States Cancer Statistics, accessed May 2020. Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race / ethnicity. Blood. 2015;125(2):410-412 ASCO (via cancer.net May 2020). 3) Howlader N, Noone AM, Krapcho M et al., SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/.

HaemaLogiX

Key products and companies in global myeloma market

Market leadership has shifted from Bristol Myers Squibb – Revlimid® product, to Janssen – Darzalex®

2024 forecast worldwide sales by class

US$23.3 billion Multiple Myeloma Market



Class	Sales (US$M)
Monoclonal	12,653
IMiD	5,397
Small molecule	3,030
CAR T	1,607
Bispecific	608

Source: EvaluatePharma, Accessed January 2024

DARZALEX® (daratumumab)

Monoclonal antibody,

Target: CD38

CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV infusion

CAR-T cell therapy,

Target: BCMA

A major market, but room for improvement

- ☒ Targets all plasma cells (malignant + normal)
- ☒ Can suppress immune response
- ☒ BCMA downregulation/resistance is common
- ☒ Patients' refractory to CD38 therapies
- ☒ 40-60% of patients fail treatment & no treatment is curative

HaemaLogiX's two new cancer targets: KMA and LMA

Targeting myeloma cancer cells with next generation immunotherapies

Two new cancer targets: KMA and LMA



Kappa Myeloma Antigen (KMA)
~70% of multiple myeloma patients



Lambda Myeloma Antigen
~30% of multiple myeloma patients

- Targets are found **on multiple myeloma plasma cells,** but not on normal, healthy plasma cells[1]
- HaemaLogiX's immunotherapies attach to these targets and trigger an immune response, **which destroys the myeloma cells**
- Multiple myeloma patients will either be **KMA (~70% of patients)** or **LMA (~30% of patients)** positive in their diagnosis

Platform potential across monoclonal antibodies, CAR T cell therapy, bispecific and tri-specific antibodies, targeting KMA or LMA

Our two, lead products target KMA

First in class, novel immunotherapies



Our two, lead products target KMA.

1. KappaMab: a Monoclonal Antibody that has completed Phase 1, 2a and 2b trials and is entering a Phase 2b dose escalation trial

2. KMA.CAR-T: a CAR-T cell therapy in Phase 1 trial, fully funded by Peter MacCallum Cancer Institute

Key addressable markets for HaemaLogiX therapies are[1]

~US$2.7 billion / ~US$210k per patient per annum
(when utilised in patients that have failed standard of care)

~US$1.2 billion / ~US$500k per patient
(as first choice or alternative therapy within fastest growing patient segment)

Source: 1) EvaluatePharma, Accessed January 2024.

Active and engaged global Scientific Advisory Board

Prof. Paul Richardson

DANA-FARBER CANCER INSTITUTE

Prof. Andrew Spencer

theAlfred

Prof. Angela Dispenzieri

MAYO CLINIC

Prof. Simon Harrison

Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia

Prof. David Gottlieb

The Westmead Institute

Prof. Mohamad Hussein

USF Health

"The HaemaLogiX platform is unique in my view because these immunotherapies ***specifically target the malignant myeloma cells and do not destroy normal plasma cells that are essential to protect our patients from serious infections,*** *which are a constant and growing challenge with other immune therapies, leading to worse outcomes and substantial cost to health care systems."*

Prof. Paul Richardson

KappaMab Phase 1 clinical trial case study

In Phase 1, KappaMab was shown to be a potentially safe and effective cancer-killing therapy

Phase 1

Patient case study[1]

Before treatment



One month after 3mg/kg treatment



- Prior to treatment, this patient's PET scan showed extensive myeloma disease in the bone marrow in the pelvic region
- After a single dose of KappaMab the patient had complete resolution of myeloma disease in the pelvis and skeleton The patient also experienced improved quality of life with reduced bone pain and normalisation of kidney function that persisted for 3 months post treatment

Source: (1) Spencer et al. Blood Cancer Journal, 2019; (9): 58.

One of my patients was in the very first study where the patients had a single dose of the molecule, and she turned out to be an exceptional responder. ***Her PET scan went from a Christmas tree to completely PET negative with a single dose of the antibody.***

Prof. Simon Harrison
HaemaLogiX Scientific Advisory Board

Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia

HaemaLogiX

KappaMab Phase 2b clinical trial results

Phase 2b results demonstrated significantly improved efficacy vs standard of care and excellent safety

Overall response rate in Phase 2b trial[1]

Population proportion; %



Legend
ORR = Overall Response Rate. **CR** = Complete Response. **VGPR** = Very Good Partial Response.
PR = Partial Response. **MR**=Minimal Response. **RD** = Revlimid + Dexamethasone. **N** = Number.
KM-Rd = KappaMab in combination with Revlimid® + Dexamethasone.

46% Reduction in the risk of death compared to matched case controls

83% vs **45%** Overall Response Rate vs matched case controls

- Excellent safety profile
- No antibody-related immune-cell toxicities
- Dramatic increase in depth of response
- Two patients in the KappaMab + Revlimid® group had CRs and remained on therapy three to five years post study

theAlfred

Source: 1) Spencer et al. Br J Haematology, 2023 Aug (4):801-811. Note: The International Myeloma Working Group criteria for reporting multiple myeloma clinical trials (Rajkumar et al. 2011, Blood 117;18:4691-4695) defines response subcategories: a partial response (PR) is ≥50% decrease in the disease biomarker called M protein, a very good partial response (VGPR) as M protein only detectable by immunofixation, complete response (CR) as no detectable M protein and a minimal response as ≥25% but less than ≤49% decrease in M protein. Overall response rate includes patients who have had a PR or greater (≥50% reduction in the M protein disease biomarker) and clinical benefit rate includes patients who have had a MR or greater (≥25% reduction in the M protein disease biomarker).

HaemaLogiX

Rationale for KMA.CAR-T cell Phase 1: pre-clinical results

An emphatic preclinical response led to a partnered Phase 1 trial for KMA.CAR-T cell therapy



- Mice treated with KMA-targeted CAR T cells **showed complete elimination of tumours, with no detectable cancer by Day 15**
- The study delivered a **durable response to 100 days, with no further deaths in the cohort given 5.0e6 CAR T** cells (a pharmaceutical industry benchmark for product development)

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to design and conduct the first Phase 1 human trial of HaemaLogiX's KMA.CAR-T cell therapy in patients with kappa-type myeloma.

Peter Mac
Peter MacCallum Cancer Foundation

What's next: two studies targeting KMA & value driving pre-clinical

Multiple clinical milestones and value inflection points over the coming 12 months

Phase 2b

- KappaMab 30mg +
- Pomalidomide/
- Dexamethasone

theAlfred

Phase 1

- KMA.CAR-T cell
- First in human

Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia

Pre-clinical

- LMA.CAR-T cell
- Bispecific antibodies
- Trispecific antibodies

Multiple clinical milestones and value inflection points

HaemaLogiX is focused on the acceleration of its strategic clinical development plan



Key partnering opportunities

Strong foundations

Supported by robust IP, orphan drug designation, and specialist investor backing

Investors

Strong support base of investors inclusive of Platinum Healthcare Fund and Smarter Capital.

Orphan Drug Status

KappaMab has been awarded **Orphan Drug Designation by US FDA for multiple myeloma** which confers a range of benefits, including potential for up to seven years1 of market exclusivity after approval.



Intellectual Property

80 patient filings across nine strategic patent families

Patent families encompass

- Composition of Matter
- Method of Use
- Dosing
- Combination

Patent life ranging from 2036 to 2045, ensuring our intellectual property is securely positioned for long-term value.

Source 1: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

Company summary

HaemaLogiX is pioneering the development of immunotherapies for patients with blood cancers and b-cell disorders

HaemaLogiX **is developing highly effective drugs for the US$23.3 billion** myeloma market - a disease which is currently incurable

Target abnormal plasma cells and **preserve immune response** demonstrated clinical unmet needs

Proven track record

46% reduction in risk of death[1] **83% vs 45%[1] overall response rate**

Clear pathway for validation and value creation

Deeply experienced Board and Management team

Partnerships and alliances **with global leaders**

Powerful and diverse IP portfolio

*Source: Spencer et al. (2023) Br J Haematology | 1. Compared to matched controls

Thank you

See more at
www.haemalogix.com

HaemaLogiX